Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma

BACKGROUND: Vemurafenib, an inhibitor of genetically activated BRAF, is now commonly prescribed for metastatic melanoma harboring a BRAF mutation. Reports on side effects have focused on cutaneous complications. We here present a case of a severe pan-uveitis associated with vemurafenib use. CASE PRE...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Sanne EJ, Meenken, Christina, Moll, Annette C, Haanen, John B, van der Heijden, Michiel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219461/
https://www.ncbi.nlm.nih.gov/pubmed/24289205
http://dx.doi.org/10.1186/1471-2407-13-561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219461/
https://www.ncbi.nlm.nih.gov/pubmed/24289205
http://dx.doi.org/10.1186/1471-2407-13-561

Ejemplares similares